Data

Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase: data

Monash University
Dr David Chalmers (Aggregated by) Dr Martin Scanlon (Associated with)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=1959.1/470443&rft.title=Fragment-based approach to the design of ligands targeting a novel site on HIV-1 integrase: data&rft.identifier=1959.1/470443&rft.publisher=Monash University&rft.description=More than 15,000 Australians and 40 million people worldwide are currently infected with HIV, which leads to acquired immunodeficiency syndrome (AIDS). HIV treatments are available that slow the progression of AIDS: these include drugs that block the action of a protein called integrase, which is essential for replication of the virus. For more than seven years, Drs Martin Scanlon and David Chalmers from Monash University worked with Drs David Rhodes and John Deadman (Avexa Ltd) and Prof Michael Parker and Dr Jerome Wielens (St. Vincent’s Institute) on a drug-design research project to develop new drugs to inhibit the HIV integrase enzyme. A combination of nuclear magnetic resonance (NMR) fragment screening, X-ray crystallography and computational studies and biological studies have produced one of the most well-established and largest datasets of this kind in this field. The project made use of facilities at the Australian Synchrotron and Chicago Synchrotron, as well as at Bio21 (University of Melbourne).&rft.creator=Dr David Chalmers&rft.date=2012&rft.relation=10.1016/j.febslet.2010.03.016&rft.relation=10.1007/s10822-005-5256-2&rft.relation=10.1002/cmdc.201000483&rft_subject=Biologically Active Molecules&rft_subject=CHEMICAL SCIENCES&rft_subject=MEDICINAL AND BIOMOLECULAR CHEMISTRY&rft_subject=Biomolecular Modelling and Design&rft_subject=Characterisation of Biological Macromolecules&rft_subject=Virology&rft_subject=BIOLOGICAL SCIENCES&rft_subject=MICROBIOLOGY&rft_subject=Human immunodeficiency virus&rft_subject=HIV&rft_subject=HIV integrase&rft_subject=Acquired immune deficiency syndrome&rft_subject=AIDS&rft_subject=Drug discovery&rft_subject=Protein structure&rft_subject=Virus replication&rft.type=dataset&rft.language=English Access the data

Access:

Other view details

Terms and conditions for released data are those of the Protein Data Bank: http://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/policies_references.html. All rights reserved for unpublished data.

Some sub-collections are freely available for download and re-use in Protein Data Bank (PDB). Further data collections may be made available to PDB in future. Access to other data is restricted to project investigators.

Full description

More than 15,000 Australians and 40 million people worldwide are currently infected with HIV, which leads to acquired immunodeficiency syndrome (AIDS). HIV treatments are available that slow the progression of AIDS: these include drugs that block the action of a protein called integrase, which is essential for replication of the virus. For more than seven years, Drs Martin Scanlon and David Chalmers from Monash University worked with Drs David Rhodes and John Deadman (Avexa Ltd) and Prof Michael Parker and Dr Jerome Wielens (St. Vincent’s Institute) on a drug-design research project to develop new drugs to inhibit the HIV integrase enzyme. A combination of nuclear magnetic resonance (NMR) fragment screening, X-ray crystallography and computational studies and biological studies have produced one of the most well-established and largest datasets of this kind in this field. The project made use of facilities at the Australian Synchrotron and Chicago Synchrotron, as well as at Bio21 (University of Melbourne).

Notes

50-200 X-ray crystallography datasets (text files); nuclear magnetic resonance (NMR) spectrometry data

Data time period: 2004

This dataset is part of a larger collection

Identifiers